NCT05750017View on ClinicalTrials.gov

A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine

PHASE1UnknownINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

March 23, 2023

Primary Completion Date

February 1, 2024

Study Completion Date

March 15, 2024

Conditions
Herpes ZosterVaccine-Preventable Diseases
Interventions
BIOLOGICAL

Low Dose Recombinant Herpes Zoster Vaccine (LZ901)

0.5 mL per dose, containing a total of 50 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.

BIOLOGICAL

High Dose Recombinant Herpes Zoster Vaccine (LZ901)

0.5 mL per dose, containing a total of 100 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.

DRUG

Placebo

0.5 mL per dose, containing 4.5 mg sodium chloride.

Trial Locations (1)

07094

RECRUITING

Frontage Clinical Services, Inc., Secaucus

Sponsors
All Listed Sponsors
lead

Beijing Luzhu Biotechnology Co., Ltd.

OTHER